DE69838789D1 - Verfahren zur behandlung oder prävention der alzheimerischen krankheit - Google Patents
Verfahren zur behandlung oder prävention der alzheimerischen krankheitInfo
- Publication number
- DE69838789D1 DE69838789D1 DE69838789T DE69838789T DE69838789D1 DE 69838789 D1 DE69838789 D1 DE 69838789D1 DE 69838789 T DE69838789 T DE 69838789T DE 69838789 T DE69838789 T DE 69838789T DE 69838789 D1 DE69838789 D1 DE 69838789D1
- Authority
- DE
- Germany
- Prior art keywords
- disease
- treating
- preventing alzheimer
- alzheimer
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3960797P | 1997-03-12 | 1997-03-12 | |
US39607P | 1997-03-12 | ||
PCT/US1998/004731 WO1998039967A1 (en) | 1997-03-12 | 1998-03-12 | A method for treating or preventing alzheimer's disease |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69838789D1 true DE69838789D1 (de) | 2008-01-10 |
DE69838789T2 DE69838789T2 (de) | 2008-10-30 |
Family
ID=21906390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69838789T Expired - Lifetime DE69838789T2 (de) | 1997-03-12 | 1998-03-12 | Verfahren zur behandlung oder prävention der alzheimerischen krankheit |
Country Status (6)
Country | Link |
---|---|
US (3) | US7300927B2 (de) |
EP (1) | EP1006794B1 (de) |
JP (2) | JP2001514663A (de) |
CA (1) | CA2323889A1 (de) |
DE (1) | DE69838789T2 (de) |
WO (1) | WO1998039967A1 (de) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69838789T2 (de) * | 1997-03-12 | 2008-10-30 | Suzanne Cambridge de la Monte | Verfahren zur behandlung oder prävention der alzheimerischen krankheit |
KR20010034417A (ko) * | 1998-01-28 | 2001-04-25 | 로즈 암스트롱 | 알츠하이머병의 치료 방법 |
US6191154B1 (en) | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
WO2000043006A1 (fr) * | 1999-01-19 | 2000-07-27 | Sankyo Company, Limited | Inhibiteur de la mort des cellules nerveuses imputable à la cytotoxicité de l'acide glutamique |
US20070179197A1 (en) * | 2000-05-01 | 2007-08-02 | Accera, Inc. | Compositions and methods for improving or preserving brain function |
US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
DK1292294T3 (da) * | 2000-05-01 | 2009-06-22 | Accera Inc | Anvendelse af mediumkæde-triglycerider til behandling og forebyggelse af Alzheimers sygdom |
US6770797B2 (en) | 2001-06-01 | 2004-08-03 | Rhode Island Hospital | Non-Transgenic nonhuman model for Alzheimer's Disease using a AD7c-NTP nucleic acid |
ATE476188T1 (de) * | 2002-05-14 | 2010-08-15 | Nipro Corp | Medikament zur prävention und behandlung von familiärer amyloid polyneuropathie |
JP2004043443A (ja) * | 2002-05-14 | 2004-02-12 | Kumamoto Technology & Industry Foundation | アミロイドーシスの予防及び治療のための医薬 |
WO2004043329A2 (en) * | 2002-11-12 | 2004-05-27 | L'oreal | Use of cellulose microbeads to make the skin matt |
US20060189545A1 (en) * | 2003-03-06 | 2006-08-24 | Henderson Samuel T | Novel chemical entities and methods for their use in treatment of metabolic disorders |
WO2005110468A2 (en) * | 2004-05-10 | 2005-11-24 | The Burnham Institute | Treatment of insulin resistance/metabolic syndrome to alleviate the risks of dementia |
US7833513B2 (en) * | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
WO2008147454A1 (en) | 2006-11-16 | 2008-12-04 | Case Western Reserve University | Selective inhibitors of translesion dna replication |
US8114847B2 (en) | 2005-03-16 | 2012-02-14 | Case Western Reserve University | Selective inhibitors of translesion DNA replication |
US20060252775A1 (en) * | 2005-05-03 | 2006-11-09 | Henderson Samuel T | Methods for reducing levels of disease associated proteins |
EP1915144A4 (de) * | 2005-06-20 | 2009-08-19 | Accera Inc | Verfahren zur reduzierung von oxidativen schäden und zur verbesserung der mitochondrien-effizienz |
KR20090003148A (ko) * | 2006-04-03 | 2009-01-09 | 액세라인크 | 나이와 관련된 기억 손상의 치료를 위한 케톤 생성조성물의 용도 |
ES2556537T3 (es) | 2007-07-31 | 2016-01-18 | Accera, Inc. | Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida |
US20090216178A1 (en) * | 2008-02-26 | 2009-08-27 | Lee Susan J | Method And Apparatus For Preventing Localized Stasis Of Cerebrospinal Fluid |
KR101734152B1 (ko) * | 2008-07-03 | 2017-05-11 | 액세라인크 | 신경계 장애의 치료를 위한 아세토아세테이트의 모노글리세리드 및 유도체 |
US8105809B2 (en) * | 2008-07-03 | 2012-01-31 | Accera, Inc. | Enzymatic synthesis of acetoacetate esters and derivatives |
SI2324126T1 (sl) * | 2008-08-12 | 2014-07-31 | Zinfandel Pharmaceuticals, Inc. | Postopek identifikacije dejavnikov tveganja za Alzheimerjevo bolezen |
US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
PL2448412T3 (pl) * | 2009-07-01 | 2019-11-29 | Jds Therapeutics Llc | Kompleksy chromu jako środki podnoszące poziom transporterów glukozy w mózgu |
KR20180050420A (ko) | 2011-01-10 | 2018-05-14 | 진판델 파마슈티컬스 인코포레이티드 | 알츠하이머 병 치료를 위한 방법 및 약품 |
EP2825546B1 (de) | 2011-09-01 | 2017-07-12 | Case Western Reserve University | Nicht-natürliche nukleoside als theranostika |
US9821173B2 (en) | 2013-02-08 | 2017-11-21 | Case Western Reserve University | Anti-cancer agents and methods of use |
KR101642042B1 (ko) * | 2013-10-24 | 2016-07-22 | 건국대학교 글로컬산학협력단 | 티아졸리딘디온의 p35 및 p25 활성 변화에 대한 용도 |
AU2017217466A1 (en) | 2016-02-11 | 2018-08-23 | Nutrition 21, Llc | Chromium containing compositions for improving health and fitness |
JP6802584B2 (ja) * | 2017-06-28 | 2020-12-16 | 国立大学法人京都大学 | アルツハイマー病の予防及び/又は治療剤 |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5522636A (en) * | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
JPS5697277A (en) * | 1980-01-07 | 1981-08-05 | Takeda Chem Ind Ltd | Thiazolidine derivative |
US5039665A (en) * | 1980-07-21 | 1991-08-13 | Markov Angel K | Use of fructose-1,6-diphosphate for treating myocardial infarction |
US4546095A (en) * | 1980-07-21 | 1985-10-08 | Markov Angel K | Use of fructose-1,6-diphosphate for treating myocardial infarction |
US4873191A (en) * | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
JPS58118577A (ja) * | 1982-01-07 | 1983-07-14 | Takeda Chem Ind Ltd | チアゾリジン誘導体 |
US4540564A (en) * | 1982-05-18 | 1985-09-10 | University Of Florida | Brain-specific drug delivery |
US4757052A (en) * | 1982-09-03 | 1988-07-12 | Markov Angel K | Method of preserving blood |
US4775665A (en) * | 1983-05-16 | 1988-10-04 | Massachusetts Institute Of Technology | Method and composition for treating neurological disorders and aging |
JPS6051189A (ja) * | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
CN1003445B (zh) * | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物,其制备方法和用途 |
AR240698A1 (es) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4965188A (en) * | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4703040A (en) * | 1985-04-03 | 1987-10-27 | Markov Angel K | Treatment of adult respiratory distress syndrome (ARDS) using fructose diphosphate (FDP) |
HU210339B (en) * | 1985-05-21 | 1995-03-28 | Pfizer | Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect |
US5039794A (en) * | 1986-09-19 | 1991-08-13 | Otsuka Pharmaceutical Co., Ltd. | Tumor egress factor and processes for producing the same |
US4873255A (en) * | 1987-02-04 | 1989-10-10 | Sankyo Company Limited | Thiazolidinone derivatives, their preparation and their use |
FI91869C (fi) * | 1987-03-18 | 1994-08-25 | Tanabe Seiyaku Co | Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi |
NL8800823A (nl) * | 1987-04-10 | 1988-11-01 | Sandoz Ag | Werkwijze voor het toepassen van dopamine-receptor agonisten en farmaceutische preparaten die deze agonisten bevatten. |
EP0295828A1 (de) * | 1987-06-13 | 1988-12-21 | Beecham Group Plc | Chemische Verbindungen |
US5232925A (en) * | 1987-09-04 | 1993-08-03 | Beecham Group P.L.C. | Compounds |
US5260445A (en) * | 1987-09-04 | 1993-11-09 | Beecham Group P.L.C. | 2,4-thiazolidinediones |
DE3856378T2 (de) * | 1987-09-04 | 2000-05-11 | Beecham Group Plc | Substituierte Thiazolidindionderivate |
US5194443A (en) * | 1987-09-04 | 1993-03-16 | Beecham Group P.L.C. | Compounds |
US4980350A (en) * | 1988-02-25 | 1990-12-25 | Merck & Co., Inc. | Piperazinylalkylpyrimidines as hypoglycemic agents |
US5223522A (en) * | 1988-03-08 | 1993-06-29 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
US5061717A (en) * | 1988-03-08 | 1991-10-29 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
US5120754A (en) * | 1988-03-08 | 1992-06-09 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
WO1989008651A1 (en) | 1988-03-08 | 1989-09-21 | Pfizer Inc. | Hypoglycemic thiazolidinedione derivatives |
US5468755A (en) * | 1988-05-10 | 1995-11-21 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Therapeutic process for the treatment of the pathologies of Type II diabetes |
US5208250A (en) * | 1988-05-25 | 1993-05-04 | Warner-Lambert Company | Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents |
US5948634A (en) | 1988-12-21 | 1999-09-07 | The General Hospital Coporation | Neural thread protein gene expression and detection of alzheimer's disease |
GB8901778D0 (en) | 1989-01-27 | 1989-03-15 | Univ Court Of The University O | Manipulatory technique |
US4897405A (en) * | 1989-04-21 | 1990-01-30 | American Home Products Corporation | Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents |
GB8919434D0 (en) * | 1989-08-25 | 1989-10-11 | Beecham Group Plc | Novel compounds |
WO1991007107A1 (en) | 1989-11-13 | 1991-05-30 | Pfizer Inc. | Oxazolidinedione hypoglycemic agents |
US5143928A (en) * | 1990-03-27 | 1992-09-01 | Warner-Lambert Company | 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents |
EP0526598B1 (de) * | 1990-04-27 | 1996-12-18 | Orion-Yhtymà Oy | Pharmakologisch aktive catecholderivate |
GB9017218D0 (en) | 1990-08-06 | 1990-09-19 | Beecham Group Plc | Novel compounds |
EP0544696B1 (de) * | 1990-08-23 | 1995-01-11 | Pfizer Inc. | Hypoglykämische hydroxyharnstoffderivate |
US5364769A (en) * | 1990-09-25 | 1994-11-15 | Genentech, Inc. | Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production |
US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
US6746678B1 (en) * | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
US5192753A (en) | 1991-04-23 | 1993-03-09 | Mcgeer Patrick L | Anti-rheumatoid arthritic drugs in the treatment of dementia |
US5143929A (en) * | 1991-05-09 | 1992-09-01 | Warner-Lambert Company | 2-substituted thiazolidinone, oxazolidinone, and imidazolidinone derivatives of fenamates as antiinflammatory agents |
US5164384A (en) * | 1991-06-19 | 1992-11-17 | Metagenics, Inc. | Anabolic mineral formula |
US5714470A (en) * | 1991-08-22 | 1998-02-03 | Merrell Pharmaceuticals, Inc. | Orally-active elastase inhibitors |
US5270319A (en) * | 1991-09-09 | 1993-12-14 | Warner-Lambert Company | 5-hydroxy-2-pyrimidinylmethylene derivatives useful as antiinflammatory agents |
US5256697A (en) * | 1992-04-16 | 1993-10-26 | Abbott Laboratories | Method of administering pyruvate and methods of synthesizing pyruvate precursors |
US5326770A (en) * | 1992-07-17 | 1994-07-05 | The Du Pont Merck Pharmaceutical Company | Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals |
IT1260155B (it) * | 1992-08-03 | 1996-03-28 | Fidia Spa | Uso terapeutico della fosforil-l-serina-n-acil-sfingosina |
GB2269992A (en) | 1992-08-14 | 1994-03-02 | Rh Ne Poulenc Rorer Limited | Powder inhalation formulations |
IL106877A (en) * | 1992-09-10 | 1998-03-10 | Lilly Co Eli | Rodinin derivatives for use as drugs for the treatment of Alzheimer's disease |
US5543297A (en) * | 1992-12-22 | 1996-08-06 | Merck Frosst Canada, Inc. | Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity |
EP0642350A4 (de) * | 1993-01-25 | 1995-06-28 | Beth Israel Hospital | Methode zur modifizierung, diagnose und dem aufspüren von igf-1 sensitiven zellbarriereeigenschaften. |
JP2710695B2 (ja) * | 1993-04-06 | 1998-02-10 | アボツト・ラボラトリーズ | ドーパミンアゴニストとしての四環式化合物 |
JP3513859B2 (ja) | 1993-04-20 | 2004-03-31 | ザ・ジェネラル・ホスピタル・コーポレーション | 神経糸状タンパク質遺伝子発現およびアルツハイマー病の検出 |
US5360614A (en) * | 1993-04-26 | 1994-11-01 | The Estee Corporation | Method of controlling the release of carbohydrates by encapsulation and composition therefor |
US5478852C1 (en) * | 1993-09-15 | 2001-03-13 | Sankyo Co | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus |
US5395822A (en) * | 1993-09-20 | 1995-03-07 | Izumi; Yukitoshi | Use of pyruvate to prevent neuronal degeneration associated with ischemia |
EP0729361A4 (de) * | 1993-11-15 | 1996-11-06 | Celtrix Pharma | Verfahren zur behandlung neurologischer erkrankungen |
CA2182731A1 (en) * | 1994-02-03 | 1995-08-10 | Michael P. Vitek | Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis |
JPH07238035A (ja) * | 1994-02-28 | 1995-09-12 | Kyowa Hakko Kogyo Co Ltd | βアミロイド蛋白質分解剤 |
US6251928B1 (en) * | 1994-03-16 | 2001-06-26 | Eli Lilly And Company | Treatment of alzheimer's disease employing inhibitors of cathepsin D |
US5534615A (en) * | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
US5594015A (en) * | 1994-06-22 | 1997-01-14 | Regents Of The University Of California | Thiazolidine derivatives for the treatment of psoriasis |
AU3146495A (en) | 1994-07-22 | 1996-02-22 | Eastern Washington University | Methods for stereotactic implantation |
US5483070A (en) * | 1994-08-02 | 1996-01-09 | Packard Instrument Company | Scintillation counter |
US5607967A (en) * | 1994-10-27 | 1997-03-04 | Merck & Co., Inc. | Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid |
US5641796A (en) * | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
US5602120A (en) * | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | Benzyl-substituted compounds having dopamine receptor affinity |
US5602121A (en) * | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | Alkyl-substituted compounds having dopamine receptor affinity |
US5824692A (en) * | 1995-01-06 | 1998-10-20 | Lippiello; Patrick Michael | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
US6022897A (en) | 1995-04-25 | 2000-02-08 | The Salk Institute For Biological Studies | Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof |
US5708012A (en) * | 1995-04-28 | 1998-01-13 | Sankyo Company, Limited | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus |
US5707971A (en) * | 1995-06-07 | 1998-01-13 | Life Resuscitation Technologies, Inc. | Modulation of glycolytic ATP production |
US5618835A (en) * | 1996-02-01 | 1997-04-08 | The Procter & Gamble Company | Dihydrobenzofuran and related compounds useful as anti-inflammatory agents |
IN182496B (de) * | 1996-02-20 | 1999-04-17 | Reddy Research Foundation | |
GB9604242D0 (en) | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
US5783556A (en) * | 1996-08-13 | 1998-07-21 | Genentech, Inc. | Formulated insulin-containing composition |
GB9627005D0 (en) | 1996-12-27 | 1997-02-12 | Knoll Ag | Therapeutic agents |
GB9627006D0 (en) | 1996-12-27 | 1997-02-12 | Knoll Ag | Therapeutic agents |
US6025157A (en) * | 1997-02-18 | 2000-02-15 | Genentech, Inc. | Neurturin receptor |
US5814647A (en) * | 1997-03-04 | 1998-09-29 | Board Of Regents, The University Of Texas System | Use of troglitazone and related compounds for the treatment of the climacteric symptoms |
DE69838789T2 (de) * | 1997-03-12 | 2008-10-30 | Suzanne Cambridge de la Monte | Verfahren zur behandlung oder prävention der alzheimerischen krankheit |
AU6959898A (en) * | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
US5925657A (en) * | 1997-06-18 | 1999-07-20 | The General Hospital Corporation | Use of PPARγ agonists for inhibition of inflammatory cytokine production |
US5789401A (en) * | 1997-08-08 | 1998-08-04 | Nutrition 21 | High-dose chromium/biotin treatment of type II diabetes |
ATE325607T1 (de) * | 1997-11-19 | 2006-06-15 | Takeda Pharmaceutical | Aptoptoseinhibitoren |
US20040058873A1 (en) * | 1998-03-12 | 2004-03-25 | Esmond Robert W. | Method for treating or preventing Alzheimer's disease |
US6028088A (en) * | 1998-10-30 | 2000-02-22 | The University Of Mississippi | Flavonoid derivatives |
US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
-
1998
- 1998-03-12 DE DE69838789T patent/DE69838789T2/de not_active Expired - Lifetime
- 1998-03-12 EP EP98909105A patent/EP1006794B1/de not_active Expired - Lifetime
- 1998-03-12 WO PCT/US1998/004731 patent/WO1998039967A1/en active IP Right Grant
- 1998-03-12 JP JP53974498A patent/JP2001514663A/ja active Pending
- 1998-03-12 CA CA002323889A patent/CA2323889A1/en not_active Abandoned
-
2003
- 2003-09-23 US US10/669,217 patent/US7300927B2/en not_active Expired - Fee Related
-
2004
- 2004-09-09 US US10/936,709 patent/US20050043242A1/en not_active Abandoned
-
2009
- 2009-06-23 JP JP2009148356A patent/JP2009280586A/ja active Pending
- 2009-07-20 US US12/505,868 patent/US20090280192A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1006794A1 (de) | 2000-06-14 |
EP1006794A4 (de) | 2004-07-07 |
JP2009280586A (ja) | 2009-12-03 |
US20090280192A1 (en) | 2009-11-12 |
JP2001514663A (ja) | 2001-09-11 |
DE69838789T2 (de) | 2008-10-30 |
EP1006794B1 (de) | 2007-11-28 |
WO1998039967A1 (en) | 1998-09-17 |
US20040060077A1 (en) | 2004-03-25 |
US7300927B2 (en) | 2007-11-27 |
US20050043242A1 (en) | 2005-02-24 |
CA2323889A1 (en) | 1998-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69838789D1 (de) | Verfahren zur behandlung oder prävention der alzheimerischen krankheit | |
DE69806970T2 (de) | Verfahren zur behandlung von hartgeweben | |
DE69227380T2 (de) | Verfahren zur bestimmung und behandlung von alzheimer-krankheit | |
DE69821913D1 (de) | Verfahren zur behandlung der hautpigmentierung | |
DE696923T1 (de) | Verfahren zur behandlung endo-ostealer materialen | |
ATE282591T1 (de) | Thioharnstoffverbindungen, zusammensetzungen sowie verfahren zur behandlung oder verhütung von entzündlichen erkrankungen und atherosklerose | |
DE69507500T3 (de) | Verfahren zur behandlung von kunststoffgiessformen | |
DE69624116T2 (de) | Verfahren zur behandlung von allergischem asthma | |
DE69807868T2 (de) | Verfahren zur behandlung von abwasserstroemen | |
DE69714828D1 (de) | Verfahren zur Behandlung von Abfallstoffen | |
KR970704445A (ko) | 페노티아진 및/또는 티옥산틴을 사용한 알츠하이머 병의 치료 및/또는 예방 방법(methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes | |
ATE257189T1 (de) | Verfahren zur behandlung von cellulosischen formkörpern | |
DE69526796T2 (de) | Verfahren zur inhibierung von pflanzenkrankheiten | |
DE69912254D1 (de) | Kosmetisches verfahren zur hautbehandlung | |
ATE371453T1 (de) | Verfahren zur behandlung von okularen neovaskularen erkrankungen | |
DE69626311T2 (de) | Zusammensetzung zur behandlung von wäsche sowie verfahren hierfür | |
DE69607559T2 (de) | Verfahren zur Behandlung von Phenolteer | |
DE69609082D1 (de) | Verfahren zur behandlung von abfällen | |
DE69307803T2 (de) | Verfahren zur elektrolytischen Behandlung | |
DE69802904D1 (de) | Verbessertes verfahren zur behandlung von aluminiummonohydratreichen bauxiten | |
DE69701726D1 (de) | Verfahren zur behandlung von knitterempfindlichen geweben | |
DE69006509T2 (de) | Verfahren zur behandlung von häuten. | |
DE69533397D1 (de) | Verfahren zur behandlung von hypertonie | |
DE69900699D1 (de) | Verfahren zur Behandlung von Schutzhüllen | |
ATA17272000A (de) | Verfahren zur behandlung von dämpfen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |